Literature DB >> 3471178

Effect of oral ofloxacin on fecal bacteria in human volunteers.

S Pecquet, A Andremont, C Tancrède.   

Abstract

Intestinal members of the family Enterobacteriaceae were eliminated in five human volunteers treated with oral ofloxacin for 5 days. No emergence of resistant Enterobacteriaceae was observed. Counts of group D streptococci were significantly reduced. Colonization by Candida sp. was observed in all five volunteers during ofloxacin treatment. The anaerobic flora was fairly stable from one sample to another before treatment and was not substantially modified by ofloxacin.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3471178      PMCID： PMC174668          DOI： 10.1128/AAC.31.1.124

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  [Practical modifications concerning the determination of antibiotics in clinical practice].

Authors:  Y CHABBERT; H BOULINGRE
Journal:  Rev Fr Etud Clin Biol       Date:  1957-06

Review 2.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Inactivation of quinolone by feces.

Authors:  J J van Saene; H K van Saene; C F Lerk
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

4.  Isolation of anaerobic bacteria from human gingiva and mouse cecum by means of a simplified glove box procedure.

Authors:  A Arank; S A Syed; E B Kenney; R Freter
Journal:  Appl Microbiol       Date:  1969-04

5.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  Effect of erythromycin on microbial antagonisms: a study in gnotobiotic mice associated with a human fecal flora.

Authors:  A Andremont; P Raibaud; C Tancrède
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

7.  Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.

Authors:  G Seibert; M Limbert; N Klesel
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

8.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  In vivo activity of nifurzide and nifuroxazide in intestinal bacteria in man and gnotobiotic mice.

Authors:  F Leonard; A Andremont; C Tancrede
Journal:  J Appl Bacteriol       Date:  1985-06
View more
  21 in total

1.  Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice.

Authors:  S Pecquet; E Chachaty; C Tancrède; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Influence of pefloxacin on microbial colonization resistance in healthy volunteers.

Authors:  E J Vollaard; H A Clasener; A J Janssen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

Review 3.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; M W DuPont
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.

Authors:  M Oethinger; A S Jellen-Ritter; S Conrad; R Marre; W V Kern
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

Review 6.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

7.  Oral ofloxacin therapy of Pseudomonas aeruginosa sepsis in mice after irradiation.

Authors:  I Brook; G D Ledney
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 8.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 9.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.

Authors:  C Dupeyron; N Mangeney; L Sedrati; B Campillo; P Fouet; G Leluan
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.